Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.09.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Wei Xiong und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Pulmonary and Critical Care Medicin…. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Hemorrhage, Neoplasms, Pyridines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Daiichi Sankyo Company, Daiichi Sankyo Chemical Pharma Co Ltd.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
BACKGROUND: The ONCO DVT study (Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis) revealed superiority of 12-month relative to 3-month edoxaban treatment for the thrombotic risk in cancer-associated isolated distal deep vein thrombosis. However, it is unknown whether the superiority could be common in different modified Ottawa score subgroups. OBJECTIVES: To identify more preferable candidates for extended anticoagulation in patients with cancer-associated isolated distal deep vein thrombosis using the modified Ottawa score. METHODS: In this post-hoc subgroup analysis of the ONCO DVT study, we stratified 601 patients into the low (≤-1, N = 126), intermediate (0, N = 323), and high (≥1, N = 152) modified Ottawa score subgroups and compared clinical outcomes between the 12-month and 3-month edoxaban treatment groups. RESULTS: The cumulative incidence of symptomatic recurrent venous thromboembolism or venous thromboembolism-related death was not different between the 12-month and 3-month edoxaban treatment groups in the low score subgroup (0.0% vs 2.2%), whereas it was lower in the 12-month than in the 3-month edoxaban treatment group in the intermediate (0.8% vs 7.6%) and high (3.1% vs 15.6%) score subgroups. There were no significant differences in the cumulative incidences of the major bleeding between the 12-month and 3-month edoxaban treatment groups in the low (10.1% vs 7.6%), intermediate (8.8% vs 5.0%), and high (13.9% vs 12.6%) score subgroups. CONCLUSION: A 12-month compared with 3-month edoxaban treatment showed a lower risk of thrombotic events in patients with cancer-associated isolated distal deep vein thrombosis in the intermediate and high modified Ottawa score subgroups but not in the low score subgroup, suggesting a limited benefit of extended anticoagulation therapy beyond 3 months in patients with low modified Ottawa score.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Pulmonary and Critical Care Medicine, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, S…
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: yyamashi@kuhp.kyoto-u.ac.jp.
- Department of Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan.
- Division of Cardiology, Shizuoka Cancer Center, Shizuoka, Japan.
- Division of Vascular Surgery, Department of Surgery, Tohoku University Hospital, Sendai, Japan.
- Division of Cardiology, Osaka General Medical Center, Osaka, Japan; Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Förderung
- Daiichi Sankyo Company
- Daiichi Sankyo Chemical Pharma Co Ltd
Zitieren
APA
Xiong, W., Yamashita, Y., Morimoto, T., Muraoka, N., Umetsu, M., Nishimoto, Y., Takada, T., Ogihara, Y., Nishikawa, T., Ikeda, N., Otsui, K., Sueta, D., Tsubata, Y., Shoji, M., Shikama, A., Hosoi, Y., Tanabe, Y., Chatani, R., Tsukahara, K., …, & ONCO DVT Study Investigators (2024). Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.09.003
Vancouver
Xiong W, Yamashita Y, Morimoto T, Muraoka N, Umetsu M, Nishimoto Y, et al. Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.09.003
BibTeX
@article{Xiong2024,
author = {Xiong, Wei and Yamashita, Yugo and Morimoto, Takeshi and Muraoka, Nao and Umetsu, Michihisa and Nishimoto, Yuji and Takada, Takuma and Ogihara, Yoshito and Nishikawa, Tatsuya and Ikeda, Nobutaka and Otsui, Kazunori and Sueta, Daisuke and Tsubata, Yukari and Shoji, Masaaki and Shikama, Ayumi and Hosoi, Yutaka and Tanabe, Yasuhiro and Chatani, Ryuki and Tsukahara, Kengo and Nakanishi, Naohiko and Kim, Kitae and Ikeda, Satoshi and Ono, Koh and Kimura, Takeshi and ONCO DVT Study Investigators, ONCO DVT Study Investigators},
title = {Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.09.003}
}
EUVIMED